Evidence map›Paper›PMID 39273516›Full record

ArticleInternational journal of molecular sciences2024

Nanopore Deep Sequencing as a Tool to Characterize and Quantify Aberrant Splicing Caused by Variants in Inherited Retinal Dystrophy Genes.

Jordi Maggi, Silke Feil, Jiradet Gloggnitzer, Kevin Maggi, Ruxandra Bachmann-Gagescu, Christina Gerth-Kahlert, Samuel Koller, Wolfgang Berger

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jordi MaggiInstitute of Medical Molecular Genetics, University of Zurich, 8952 Schlieren, Switzerland.ORCID 0000-0002-9906-8739
Silke FeilInstitute of Medical Molecular Genetics, University of Zurich, 8952 Schlieren, Switzerland.
Jiradet GloggnitzerInstitute of Medical Molecular Genetics, University of Zurich, 8952 Schlieren, Switzerland.
Kevin MaggiInstitute of Medical Molecular Genetics, University of Zurich, 8952 Schlieren, Switzerland.ORCID 0000-0002-1333-7070
Ruxandra Bachmann-GagescuInstitute of Medical Genetics, University of Zurich, 8952 Schlieren, Switzerland.ORCID 0000-0002-3571-5271
Christina Gerth-KahlertDepartment of Ophthalmology, University Hospital Zurich and University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0001-6298-615X
Samuel KollerInstitute of Medical Molecular Genetics, University of Zurich, 8952 Schlieren, Switzerland.ORCID 0000-0003-0965-0539
Wolfgang BergerInstitute of Medical Molecular Genetics, University of Zurich, 8952 Schlieren, Switzerland.ORCID 0000-0002-0370-3815

Funding

Velux Stiftung 1371
6 · The paper itself

Abstract

The contribution of splicing variants to molecular diagnostics of inherited diseases is reported to be less than 10%. This figure is likely an underestimation due to several factors including difficulty in predicting the effect of such variants, the need for functional assays, and the inability to detect them (depending on their locations and the sequencing technology used). The aim of this study was to assess the utility of Nanopore sequencing in characterizing and quantifying aberrant splicing events. For this purpose, we selected 19 candidate splicing variants that were identified in patients affected by inherited retinal dystrophies. Several in silico tools were deployed to predict the nature and estimate the magnitude of variant-induced aberrant splicing events. Minigene assay or whole blood-derived cDNA was used to functionally characterize the variants. PCR amplification of minigene-specific cDNA or the target gene in blood cDNA, combined with Nanopore sequencing, was used to identify the resulting transcripts. Thirteen out of nineteen variants caused aberrant splicing events, including cryptic splice site activation, exon skipping, pseudoexon inclusion, or a combination of these. Nanopore sequencing allowed for the identification of full-length transcripts and their precise quantification, which were often in accord with in silico predictions. The method detected reliably low-abundant transcripts, which would not be detected by conventional strategies, such as RT-PCR followed by Sanger sequencing.

Indexed as

High-Throughput Nucleotide SequencingNanopore SequencingRetinal DystrophiesAlternative SplicingExonsHumansRNA Splicingexon skippinginherited retinal dystrophies (IRDs)long-read sequencingminigene assayNanoporepseudoexonsplice variantsplicing

Identifiers

PMID39273516
PMCPMC11395040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.